<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127837">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437995</url>
  </required_header>
  <id_info>
    <org_study_id>ADV115922</org_study_id>
    <nct_id>NCT01437995</nct_id>
  </id_info>
  <brief_title>Long-acting Beta Agonist Step Down Study</brief_title>
  <acronym>LASST</acronym>
  <official_title>Long-acting Beta Agonist Step Down Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 56-week, multi-center, blinded, randomized, double-masked parallel group
      comparative effectiveness study of approaches to stepping down therapy for patients with
      well-controlled asthma treated with combination ICS and LABA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current asthma guidelines recommend stepping down therapy once asthma is controlled for at
      least 3 months. For patients treated with inhaled corticosteroids (ICS) alone, a dose
      reduction of 25-50% to a minimal dose that controls disease is recommended. The optimal
      approach to reducing treatment in patients with asthma treated with combination inhaled
      corticosteroids and long-acting beta agonists (ICS/LABA) is not clear. The American Lung
      Association Asthma Clinical Research Center (ALAACRC) is a network of 18 asthma research
      centers with the goal of performing clinical trials directly relevant to clinical practice.
      The question of the optimal way to de-escalate therapy in patients with asthma that is well
      controlled on fixed dose combination ICS/LABA is a key question for practitioners caring for
      patients with moderate to severe persistent asthma. We propose a 56 week multi-center,
      prospective, randomized, three-arm parallel group comparative effectiveness study comparing
      three approaches to care of patients with asthma well-controlled for three months on
      combination ICS/LABA: reduction of ICS dose and maintenance of LABA, initial discontinuation
      of LABA with continuation of ICS, and continuation of stable dose ICS/LABA. Our primary goal
      is to perform a pragmatic study that resembles clinical practice and determine the optimal
      treatment strategy that results in the lowest rate of treatment failure over 48 weeks of
      follow-up. Additional exploratory analyses include assessing risk factors for step-down
      failure, and to assess the duration of time that asthma control is maintained when therapy
      is de-escalated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>Rate of treatment failures assessed by decline in peak flow or FEV1, increased need for beta agonists, requirement for non-scheduled medical care for asthma symptoms, or prednisone taper.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Pulmonary function measures: 1)morning peak expiratory flow rate (from the patients' daily diary cards) and 2)pre-BD FEV1 and bronchodilator response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of episodes of poor asthma control</measure>
    <time_frame>48 weeks</time_frame>
    <description>Rate of episodes of poor asthma control (EPAC) defined by unscheduled medical care, hospitalization, use of oral corticosteroids and/or increased use of rescue medications and/or decrease of 30% or more in morning PEFR</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone/Salmeterol Diskus 250/50 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone/Salmeterol Diskus 100/50 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Diskus alone 250 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Salmeterol Diskus</intervention_name>
    <description>Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily</description>
    <arm_group_label>Fluticasone/Salmeterol Diskus 250/50 ug</arm_group_label>
    <other_name>Fluticasone</other_name>
    <other_name>Salmeterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Salmeterol Diskus</intervention_name>
    <description>Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily</description>
    <arm_group_label>Fluticasone/Salmeterol Diskus 100/50 ug</arm_group_label>
    <other_name>Fluticasone</other_name>
    <other_name>Salmeterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Diskus</intervention_name>
    <description>Fluticasone Diskus alone 250 ug twice daily without Salmeterol</description>
    <arm_group_label>Fluticasone Diskus alone 250 ug</arm_group_label>
    <other_name>Fluticasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 12-80 years

          -  physician diagnosed asthma that is well-controlled on moderate dose ICS/LABA based on
             an Asthma Control Test (ACT) score more than or equal to 20, and the absence of
             unscheduled visits or use of rescue prednisone for 4 weeks prior to enrollment

          -  pre-bronchodilator FEV1 more than or equal to 70% predicted

        Exclusion Criteria:

          -  chronic oral steroid therapy

          -  hospitalization or urgent care visit within 4 weeks of the screening visit

          -  lung disease other than asthma including COPD, bronchiectasis, sarcoidosis or other
             lung disease

          -  less than 10 pack/yr of tobacco use and abstinence for at least 1 yr

          -  history of extensive environmental tobacco exposure or occupational exposure
             suggestive of possible COPD per judgment of investigator

          -  post bronchodilator FEV1 less than 70% predicted

          -  near fatal asthma (intubation or ICU admission for asthma) within 2 yrs of enrollment

          -  high risk of near fatal or fatal asthma

          -  history of known premature birth less than 33 weeks or any significant level of
             respiratory care including prolonged oxygen administration or mechanical ventilation
             during the neonatal period

          -  unstable cardiac disease (decompensated CHF, unstable angina, recent MI, atrial
             fibrillation, supraventricular or ventricular tachycardia, congenital heart disease,
             or severe uncontrolled hypertension)

          -  other major chronic illnesses which in the judgment of the study physician would
             interfere with participation in the study e.g. including but not limited to
             uncontrolled diabetes, uncontrolled HIV infection or other immune system disorder

          -  drug allergies to any component of study drug or history of adverse reaction to short
             or long acting beta agonists

          -  for women of child bearing potential; not pregnant, not lactating and agree to
             practice an adequate birth control method (abstinence, combination barrier and
             spermicide, or hormonal) for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Wise, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Rogers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona, Arizona Respiratory Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Illinois Consortium</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hofstra North Shore-LIJ School of Medicine</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New England Consortium</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lungusa.org/</url>
    <description>American Lung Association</description>
  </link>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 26, 2016</lastchanged_date>
  <firstreceived_date>September 5, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Robert A. Wise</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Step down therapy</keyword>
  <keyword>Inhaled corticosteroids</keyword>
  <keyword>Long-acting beta agonists</keyword>
  <keyword>Fluticasone Salmeterol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
